PDCD1 and classic Hodgkin lymphoma: PD-1 blockade using nivolumab or pembrolizumab has dramatically improved the prognosis of relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) and is now a well-recognized therapeutic option in this setting [10,11,12].